COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Formycon reports successful financial year 2024 with strong operational progress and market position enhancement. Key milestones achieved in biosimilar development. Financial outlook for 2025 provided -
-
-
COMMUNIQUÉ DE PRESSE
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Formycon announces conference call for fiscal year 2024 results and participation in investor conferences in Q2 2025 -
-
-
COMMUNIQUÉ DE PRESSE
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, officially launched in the United States and European Union, offering comparable efficacy and safety. Formycon AG and Fresenius ensure successful market access
